1. Home
  2. STTK vs SHMD Comparison

STTK vs SHMD Comparison

Compare STTK & SHMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • SHMD
  • Stock Information
  • Founded
  • STTK 2016
  • SHMD 1864
  • Country
  • STTK United States
  • SHMD Germany
  • Employees
  • STTK N/A
  • SHMD N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • SHMD
  • Sector
  • STTK Health Care
  • SHMD
  • Exchange
  • STTK Nasdaq
  • SHMD Nasdaq
  • Market Cap
  • STTK 37.6M
  • SHMD 123.6M
  • IPO Year
  • STTK 2020
  • SHMD N/A
  • Fundamental
  • Price
  • STTK $0.83
  • SHMD N/A
  • Analyst Decision
  • STTK Hold
  • SHMD
  • Analyst Count
  • STTK 4
  • SHMD 0
  • Target Price
  • STTK $3.00
  • SHMD N/A
  • AVG Volume (30 Days)
  • STTK 401.8K
  • SHMD 16.7K
  • Earning Date
  • STTK 07-31-2025
  • SHMD 02-25-2025
  • Dividend Yield
  • STTK N/A
  • SHMD N/A
  • EPS Growth
  • STTK N/A
  • SHMD N/A
  • EPS
  • STTK N/A
  • SHMD N/A
  • Revenue
  • STTK $4,606,000.00
  • SHMD $85,165,542.00
  • Revenue This Year
  • STTK N/A
  • SHMD N/A
  • Revenue Next Year
  • STTK N/A
  • SHMD N/A
  • P/E Ratio
  • STTK N/A
  • SHMD N/A
  • Revenue Growth
  • STTK 69.65
  • SHMD N/A
  • 52 Week Low
  • STTK $0.69
  • SHMD $1.86
  • 52 Week High
  • STTK $4.99
  • SHMD $5.17
  • Technical
  • Relative Strength Index (RSI)
  • STTK 39.19
  • SHMD N/A
  • Support Level
  • STTK $0.77
  • SHMD N/A
  • Resistance Level
  • STTK $0.91
  • SHMD N/A
  • Average True Range (ATR)
  • STTK 0.08
  • SHMD 0.00
  • MACD
  • STTK -0.02
  • SHMD 0.00
  • Stochastic Oscillator
  • STTK 16.23
  • SHMD 0.00

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

Share on Social Networks: